36 results
6-K
EX-99.2
IMCR
Immunocore Holdings plc
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
forward to be offset against future taxable profits. No deferred tax asset is recognized in respect of accumulated tax losses in the United Kingdom … . This decrease was partially offset by GSK electing not to progress the final program under the collaboration during the three months ended September
6-K
EX-99.2
IMCR
Immunocore Holdings plc
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
be able to file under a large company scheme.
Un-surrendered tax losses are carried forward to be offset against future taxable profits. No deferred … . This increase of £0.1 million was primarily attributable to an increase in internal research and development expenses of £1.4 million partially offset
6-K
EX-99.2
IMCR
Immunocore Holdings plc
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
company. However, we may be able to file under a large company scheme.
Un-surrendered tax losses are carried forward to be offset against future … a change in program focus partially offset by a reduction in revenue of £0.4 million arising from the change in estimate noted below. The increase
6-K
EX-99.2
IMCR
Immunocore Holdings plc
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
losses are carried forward to be offset against future taxable profits. No deferred tax asset is recognized in respect of accumulated tax losses … these product candidates through clinical trials. Our costs on our IMC-M113V program for HIV also increased by £1.0 million. These increases were offset
6-K
EX-99.2
IMCR
Immunocore Holdings plc
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
provisions may also apply.
Un-surrendered tax losses are carried forward to be offset against future taxable profits. No deferred tax asset … significant changes in the rate between pounds sterling and the U.S dollar. These gains were partially offset by an increase in Selling and other
6-K
EX-99.2
6ht5xwuzh2e
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
72m gjfo7cpmgdei77t8
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
m4owzenmkvkye2uvmv72
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.2
qda mxg3xaa
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
jtpxa
10 May 23
Current report (foreign)
7:27am
10-Q
qzbelz
8 May 24
Quarterly report
7:00am
6-K
EX-99.1
bya6b16p
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
trmf2g
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
10-K
wa1y2h99ddf
28 Feb 24
Annual report
7:33am
6-K
EX-99.1
ozckpfbn
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
20-F
t3mwdk9
25 Mar 21
Annual report (foreign)
7:01am
6-K/A
EX-99.1
dip023k
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
F-1/A
7ydzn20ekj8
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
c4k5jcq9ercqdx
3 Feb 21
Registration statement (foreign) (amended)
5:22pm